Eton Pharmaceuticals reported a 73% increase in Q1 2026 product sales to $24.3 million, driven by strong growth across its rare disease portfolio and new product launches including DESMODA and HEMANGEOL. The company raised its full-year 2026 revenue guidance to over $120 million from $110 million, citing early success with new products and ongoing clinical studies. Eton also advanced its R&D pipeline with clinical trials for ET-700 and label expansion studies, positioning for long-term growth in rare disease treatments.
Riskified Ltd. posted strong Q2 2026 results with revenue rising 22% year-over-year to $98.69 million, its best growth in over four years, driven by rising demand for its e-commerce fraud prevention services. However, earnings per share came in at $0...
Outlook Therapeutics has seen its analyst consensus price target increase from $1.90 to $2.80, driven by promising Phase III trial results for its eye disease drug ONS-5010 and strategic partnerships. The company is expected to beat upcoming quarterl...
Ball Corporation's stock has gained 3.14% over the past month but recently dropped 4.52%, presenting a potential buying opportunity. Analysts forecast a 20.27% growth potential with a target price of $75, reflecting confidence in the company's future...
Kyndryl Holdings, an IT infrastructure services provider spun off from IBM, has seen its stock rise nearly 12% over the past 30 days but recently dipped 3.77% in the last 10 days, possibly creating a buying opportunity. Analysts forecast a 12.85% ups...
The Honest Company reported Q2 earnings of $0.04 per share, doubling expectations, despite a 10.9% revenue drop due to strategic business exits. Organic revenue grew 6.7%, showing strength in core products, while profitability improved with a gross m...
